The full universe. 517 verified biotech investors, sortable and searchable.

The companion data layer to The Biotech Capital Report. All 517 verified equity investors meeting the n≥5 threshold across the 11-year observation window (2015-2026). Search by firm name. Filter by tier, investor type, or sample-size confidence. Click any row for the underlying numbers and structural context.

← Return to the report

THE FULL TIER LIST

517 verified investors. Search, filter, sort, expand.

Tier 1 firms re-up in 50% or more of their portfolio. Tier 2 covers 30-49%. Tier 3 sits below 30%. Sample-size confidence is tagged on every row. Limited-sample rows (n=5-9) are flagged in the Sample column to reflect lower statistical reliability.

Showing 517 of 517

Firm Type Sample N Exit % FO %

Reading the table. Follow-on rate is the percentage of a firm's portfolio companies in which they participated in two or more financing rounds within the 2015-2026 window. Exit rate is the percentage of portfolio companies with status Acquired or Public, computed across all years. Sample-size tag indicates portfolio breadth in the analytical window. Limited-sample rows (n=5-9) are flagged in the Sample column to reflect lower statistical reliability — a single different outcome materially shifts the rate. Click any row for the structural detail.

GO DEEPER

Need this sliced for your company?

On request, we produce custom reports — by modality, therapeutic area, technology platform, and stage. Read the full analysis, or the methodology behind these tiers.

Read the Biotech Capital Report 2026 → Methodology →

Request a custom cut, or tell us if we’ve mischaracterised your firm — we welcome corrections.

By downloading, you agree to our Privacy Notice.